Myocardial Proteome in Human Heart Failure With Preserved Ejection Fraction
Journal of the American Heart Association · 13.03.2025
DOI: 10.1161/jaha.124.038945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, online erschienen am 13.03.2025. Verfasst von Vivek P Jani und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine Johns Hopkins University School of Medicine Baltimore MD USA. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Proteome, Myocardium. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIH HHS, NIAID NIH HHS.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Heart failure with preserved ejection fraction (HFpEF) constitutes more than half of all HF but has few effective therapies. Recent human myocardial transcriptomics and metabolomics have identified major differences between HFpEF and controls. How this translates at the protein level is unknown. Methods and Results Myocardial tissue from patients with HFpEF and nonfailing donor controls was analyzed by data‐dependent acquisition (n=10 HFpEF, n=10 controls) and data‐independent acquisition (n=44 HFpEF, n=5 controls) mass spectrometry‐based proteomics. Differential protein expression analysis, pathway overrepresentation, weighted coexpression network analysis, and machine learning were integrated with clinical characteristics and previously reported transcriptomics. Principal component analysis (data‐dependent acquisition‐mass spectrometry) found HFpEF separated into 2 subgroups: one similar to controls and the other disparate. Downregulated proteins in HFpEF versus controls were enriched in mitochondrial transport/organization, translation, and metabolism including oxidative phosphorylation. Proteins upregulated in HFpEF were related to immune activation, reactive oxygen species, and inflammatory response. Ingenuity pathway analysis predicted downregulation of protein translation, mitochondrial function, and glucose and fat metabolism in HFpEF. Expression of oxidative phosphorylation and metabolism genes (higher) versus proteins (lower) was discordant in HFpEF versus controls. Data‐independent acquisition‐mass spectrometry proteomics also yielded 2 HFpEF subgroups; the one most different from controls had a higher proportion of patients with severe obesity and exhibited lower proteins related to fuel metabolism, oxidative phosphorylation, and protein translation. Three modules of correlated proteins in HFpEF that correlated with left ventricular hypertrophy and right ventricular load related to (1) proteasome; (2) fuel metabolism; and (3) protein translation, oxidative phosphorylation, and sarcomere organization.
Conclusions
Integrative proteomics, transcriptomics, and pathway analysis supports a defect in both metabolism and translation in HFpEF. Patients with HFpEF with more distinct proteomic signatures from control more often had severe obesity, supporting therapeutic efforts targeting metabolism and translation, particularly in this subgroup.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine Johns Hopkins University School of Medicine Baltimore MD USA.
- Advanced Clinical Biosystems Research Institute, The Smidt Heart Institute, Cedars-Sinai Medical Center Los Angeles CA USA.
- Department of Biochemistry Albert Einstein College of Medicine Bronx NY USA.
- Department of Pathology Albert Einstein College of Medicine Bronx NY USA.
- Department of Pharmacology and Molecular Sciences, and Department of Biomedical Engineering Johns Hopkins University Baltimore MD USA.
ORCID-Profile: Vivek P Jani, Edwin J Yoo, Aleksandra Binek, Alina Guo, Jennifer Aguilan, Kavita Sharma, Jennifer E Van Eyk, David A Kass, Virginia S Hahn
Förderung
- NHLBI NIH HHS
- NIH HHS
- NIAID NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Jani, V. P., Yoo, E. J., Binek, A., Guo, A., Kim, J. S., Aguilan, J., Keykhaei, M., Jenkin, S. R., Sidoli, S., Sharma, K., Van Eyk, J. E., Kass, D. A., & Hahn, V. S. (2025). Myocardial Proteome in Human Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.038945
Vancouver
Jani VP, Yoo EJ, Binek A, Guo A, Kim JS, Aguilan J, et al. Myocardial Proteome in Human Heart Failure With Preserved Ejection Fraction. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.038945
BibTeX
@article{Jani2025,
author = {Jani, Vivek P and Yoo, Edwin J and Binek, Aleksandra and Guo, Alina and Kim, Julie S and Aguilan, Jennifer and Keykhaei, Mohammad and Jenkin, Sydney R and Sidoli, Simone and Sharma, Kavita and Van Eyk, Jennifer E and Kass, David A and Hahn, Virginia S},
title = {Myocardial Proteome in Human Heart Failure With Preserved Ejection Fraction},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.038945}
}
EUVIMED